Brief: Biophytis Gives Update On Sarconeos Programs

Biophytis SA

26/04/2021 07:18

April 26 (Reuters) - BIOPHYTIS SA  ALBPS.PA :
    * BIOPHYTIS GIVES OPERATIONAL PERSPECTIVES ON ITS SARCONEOS
(BIO101) AHEAD OF ITS UPCOMING AGM ON APRIL 26, 2021
    * COVA PHASE 2-3 STUDY AGAINST COVID-19: ASSUMING EMERGENCY
USE
AUTHORIZATION FROM US, AND CONDITIONAL MARKET APPROVAL FROM EMA
ARE OBTAINED IN Q3 2021, MARKETING PREPARATION COULD POSSIBLY
START BY END OF 2021
    * RESULTS FROM ONGOING PHASE 2 SARA-INTEREST TRIAL IN
SARCOPENIA
EXPECTED BEFORE END OF Q2 2021
    * COVA PHASE 2-3 STUDY AGAINST COVID-19: MOST OF
COMMERCIALIZATION
WOULD BE ENVISAGED FROM START OF 2022
    * INTENDS TO RESUME PREPARATION FOR LAUNCHING MYODA PHASE
1/2
CLINICAL TRIAL OF SARCONEOS (BIO101) IN DUCHENNE MUSCULAR
DYSTROPHY (DMD), WHICH COULD NOW BE INITIATED IN MID-2021
    * COVA PHASE 2-3 STUDY AGAINST COVID-19: IN THAT
PERSPECTIVE,
BIOPHYTIS IS CURRENTLY TAKING STEPS IN ORDER TO PREPARE FOR
INDUSTRIAL SCALE UPS AND MANUFACTURING WITH POTENTIAL CMO
PARTNERS IN DUE COURSE
    * SARA-INTEREST PHASE 2 STUDY IN SARCOPENIA: DEPENDING ON
RESULTS
FROM ONGOING PHASE 2 SARA-INTEREST TRIAL IN SARCOPENIA, WHICH
ARE EXPECTED BEFORE END OF Q2 2021, BIOPHYTIS COULD INITIATE A
PHASE 3 STUDY OF SARCONEOS (BIO101) IN SAME INDICATION
    * SARA-INTEREST PHASE 2 STUDY IN SARCOPENIA: AMONGST OTHER
OPTIONS, COMPANY MAY CONSIDER PARTNERING ON THIS STUDY, WHICH
COULD START IN EARLY 2022

Source text for Eikon:  ID:nGNXbnYjcc 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00 ;))